METASTATIC BREAST CANCER

This study tested a new drug called taselisib, which blocks a protein that helps cancer grow, combined with standard HER2-targeted therapies in 68 people with advanced HER2+ breast cancer. The main goal was to find the safest dose for future studies. Researchers also looked at wh…

This study tested the drug trastuzumab, given directly into the spinal fluid, for people with HER2-positive breast cancer that spread to the lining of the brain (carcinomatous meningitis). The first part found the safest dose, and the second part checked if it could slow down ner…

This study tested whether changing hormone therapy (from an aromatase inhibitor to fulvestrant) when a blood test detects a specific genetic change (ESR1 mutation) can help women with advanced, hormone-sensitive breast cancer live longer without their cancer growing. Over 1,000 p…

This study tested a drug called HER3-DXd in 63 adults with breast cancer, lung cancer, or other solid tumors that had spread to the brain or the lining around the brain and spinal cord. The goal was to see if the drug could shrink brain tumors or help patients live longer. Partic…

This study tested a new treatment combination for people with advanced breast cancer that has stopped responding to standard therapies. The treatment uses a personalized vaccine (SV-BR-1-GM) plus an immunotherapy drug (retifanlimab) to help the immune system fight the cancer. The…

This early-phase study tested a new drug combination for people with advanced HER2-positive breast cancer that has a specific gene change (PIK3CA mutation). The goal was to find a safe dose of the study drug ipatasertib when given with two standard drugs (pertuzumab and trastuzum…

This study tested an experimental drug called U3-1402 (patritumab deruxtecan) in 121 people with advanced or metastatic breast cancer. The goal was to see if the drug could shrink tumors and to check for side effects. The drug is designed to target cancer cells directly, and the …

This early-phase trial tested a combination of four therapies to train the immune system to attack cancer. 17 adults with non-Hodgkin's lymphoma, metastatic breast cancer, or head and neck cancer received low-dose radiation, an immune cell booster (Flt3L), an immune activator (Po…

This early-phase trial tested a combination of three drugs—olaparib, palbociclib, and fulvestrant—in 9 people with advanced, hormone receptor-positive breast cancer who also have BRCA1 or BRCA2 mutations. The main goal was to see if the combination is safe and to measure how long…

This early-phase study tested whether giving a type of focused radiation (stereotactic radiosurgery) after an immunotherapy drug (nivolumab) is safe and can help control breast cancer that has spread to the brain. Fourteen adults with up to 10 brain metastases took part. The main…

This study tested whether adding the drug samuraciclib to standard hormone therapy (fulvestrant) works better than fulvestrant alone for people with a certain type of advanced breast cancer (HR-positive, HER2-negative). The trial included 60 adults whose cancer had worsened despi…

This study tested a new two-drug combination (samuraciclib and elacestrant) in 49 adults with a specific type of advanced breast cancer (HR+/HER2-). The goal was to see if the combination is safe and can slow down the cancer's growth. Participants had already tried other treatmen…

This study looked at whether adding focused radiation to the usual drug therapy can help people with breast cancer that has spread to a small number of spots (up to 5). The goal was to see if it could delay the cancer from growing and improve quality of life. 87 participants were…

This study tested a combination of two drugs, palbociclib and tamoxifen, as a first treatment for women with a certain type of advanced breast cancer (HR+/HER2-). The goal was to see how long the cancer could be kept from growing. 49 women took part, and the study measured how lo…

This study looked at how well anti-HER2 drugs work in Egyptian women with HER2-positive breast cancer, an aggressive type. Researchers followed 80 patients to see if single or combination therapy improved survival and safety. The goal was to understand real-world effectiveness in…

This study looked at whether a 6-month physical activity program using a fitness tracker could help women with metastatic breast cancer feel better and have less fatigue. 124 women were randomly assigned to either get activity recommendations plus a tracker and walking sessions, …

This study tested a counseling program called CALM (Managing Cancer and Living Meaningfully) for people with malignant brain cancer. The goal was to see if it's practical and helpful for reducing distress like depression and anxiety about death. 60 participants were offered eithe…

This study looked at how a drug called alpelisib affects blood sugar in people with metastatic breast cancer. Eight patients wore a continuous glucose monitor for months to track sugar levels day and night. The goal was to better understand and manage high blood sugar, a common s…

This study observed 185 people with HR+/HER2- metastatic breast cancer in Africa and the Middle East who were starting treatment with palbociclib combined with hormone therapy. Researchers tracked how long the treatment kept the cancer from growing, overall survival, and quality …

This study looked at 559 adults in Israel with metastatic breast cancer who were prescribed palbociclib as part of their treatment. Researchers tracked how long patients stayed on the drug, what doses they used, and what treatments they received next. The goal was to understand r…

This study examined whether specific gene variations influence how well metastatic breast cancer patients respond to chemotherapy with or without the drug bevacizumab. Researchers enrolled 307 participants from Italy and analyzed their genetic profiles alongside treatment outcome…

This study looked at information from about 20,000 women with metastatic breast cancer to see if other measures, besides overall survival, could be used to judge how well treatments work. Researchers compared real-world data from medical records with results from clinical trials.…

This study looked at 65 people with advanced HER2-negative breast cancer who have certain gene mutations. Researchers used a test called RAD51-foci to see if it could predict how well the drug olaparib would work. The goal was to find a better way to match patients with the right…

This study looked at 60 people with metastatic breast cancer to find out if certain cells in their blood (called CK+/CD45+ double-positive cells) come from the tumor. Researchers took a blood sample before starting treatment and checked archived tumor samples. The goal was to bet…

This study interviewed 48 adults with HR+/HER2- metastatic breast cancer who had taken capivasertib plus fulvestrant for at least one week. Researchers wanted to learn about patients' attitudes toward the dosing schedule and any side effects that affected their ability to stay on…

This study looked at 22 adults with advanced HER2-positive or HER2-low breast cancer who were taking the drug trastuzumab deruxtecan (T-DXd). Researchers wanted to see how often patients stopped treatment early or needed dose changes in everyday medical practice. The goal was to …